Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Rbv-Weeks'

Rbv-Weeks published presentations and documents on DocSlides.

MK3 MK3 + RBV
MK3 MK3 + RBV
by min-jolicoeur
Randomisation. Open-label. W8. * Liver biopsy or ...
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
by UnicornLove
C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N =...
Daclatasvir + Sofosbuvir + RBV in GT3
Daclatasvir + Sofosbuvir + RBV in GT3
by sophia2
. with Advanced Liver Disease. ALLY-3+ Study. Phas...
PEG alfa-2a RBV versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
SOF + EBR + GZR + RBV
SOF + EBR + GZR + RBV
by test
N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...
M.W. Fried , 1 M. Buti,
M.W. Fried , 1 M. Buti,
by iamamercy
2. G.J. Dore,. 3. P. Ferenci,. 4. . I. Jacobson...
Hepatitis C Imtiaz Alam, M.D.
Hepatitis C Imtiaz Alam, M.D.
by olivia-moreira
Medical Director, Austin Hepatitis Center. 1. Hep...
Chronic hepatitis C: guidelines for screening and
Chronic hepatitis C: guidelines for screening and
by aaron
treatment. Lisa M. Glass, MD. Clinical Lecturer. ...
Open-label
Open-label
by pamella-moone
* Liver biopsy or . Fibroscan. ≤. 12.5 . kPa....
C-WORTHY/B
C-WORTHY/B
by stefany-barnette
Randomisation*. Open-label. >. 18 years. HCV ...
How to optimize treatment of G1 patients?
How to optimize treatment of G1 patients?
by KissesForYou
Prof. G. K. K. Lau 2012. Standard of care (SOC) ...
NS5A and polymerase inhibitors
NS5A and polymerase inhibitors
by LoveBug
Mark Sulkowski, MD. Professor of Medicine. Johns H...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by webraph
Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...
Prevention strategies for HIV/HCV co infection
Prevention strategies for HIV/HCV co infection
by giovanna-bartolotta
Isabelle Andrieux-Meyer, MD. Médecins Sans Front...
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection
by karlyn-bohler
John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by lois-ondreau
Sameh W. Boktor, MD, MPH. Medical Epidemiologist....
C-WORTHY Study Part
C-WORTHY Study Part
by karlyn-bohler
D : . grazoprevir. . + . elbasvir. + RBV in ge...
Randomisation
Randomisation
by pamella-moone
*. 1:1. Open-label. ≥ 18 years. HCV genotype ...
Hepatitis C Drug Pipeline
Hepatitis C Drug Pipeline
by cheryl-pisano
HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...
Design
Design
by test
PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV...
David Fletcher, MD
David Fletcher, MD
by tatiana-dople
Department of Medicine. University of Toronto. Co...
Out With the Old and In With the New, Again?
Out With the Old and In With the New, Again?
by test
Out With the Old, In With the New. Current Standa...
HIV and HCV Update for the Pharmacist – June 2014
HIV and HCV Update for the Pharmacist – June 2014
by marina-yarberry
John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...
GZR + EBR
GZR + EBR
by celsa-spraggs
C-WORTHY Study Part C: . grazoprevir. . + . elba...
SOF/VEL
SOF/VEL
by trish-goza
400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV...
WEEKS ENDING LOG 2014-2015
WEEKS ENDING LOG 2014-2015
by giovanna-bartolotta
Weeks Weeks Ending Ending Saturday Saturday Weeks...
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
by badra
Duke University School of Medicine. Durham, North ...
Are (exogenous) interferons
Are (exogenous) interferons
by amey
really necessary?. Peter . Ferenci. Medical Univer...
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
by daisy
B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by myesha-ticknor
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by cheryl-pisano
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
OBV/PTV/r DSV Open label
OBV/PTV/r DSV Open label
by kittie-lecroy
≥ 18 years. Chronic HCV infection. Genotype 1. ...
OBV/PTV/r DSV RBV OBV/PTV/r
OBV/PTV/r DSV RBV OBV/PTV/r
by ellena-manuel
DSV . placebo. Randomisation*. Partial blind. 1...
Peginterferon alfa-2a +
Peginterferon alfa-2a +
by stefany-barnette
RBV . versus. Interferon alfa. -. 2a + RBV . ACT...
COSMOS
COSMOS
by sherrill-nordquist
SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 ...